Shanda Asset Management Holdings’s Supernus Pharmaceuticals SUPN Stock Holding History

Shanda Asset Management Holdings’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,000	Closed	-$331K	–	40
2019 Q2	$331K	Hold	10,000	–	–	0.06%	30
2019 Q1	$350K	Hold	10,000	–	–	0.06%	46
2018 Q4	$332K	Hold	10,000	–	–	0.06%	43
2018 Q3	$504K	Hold	10,000	–	–	0.08%	33
2018 Q2	$599K	Hold	10,000	–	–	0.09%	46
2018 Q1	$458K	Hold	10,000	–	–	0.08%	35
2017 Q4	$399K	Hold	10,000	–	–	0.06%	41
2017 Q3	$400K	Hold	10,000	–	–	0.05%	35
2017 Q2	$431K	Hold	10,000	–	–	0.07%	29
2017 Q1	$313K	Hold	10,000	–	–	0.05%	31
2016 Q4	$253K	Hold	10,000	–	–	0.05%	25
2016 Q3	$247K	Buy	+10,000	New	+$226K	0.04%	22

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return

Shanda Asset Management Holdings's SUPN Position: Q3 2019 in Review

Shanda Asset Management Holdings sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 10,000 shares — an estimated $331K sold.

Shanda Asset Management Holdings first reported a position in SUPN in Q3 2016 and held it in 12 quarters. The position peaked at $599K in Q2 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

Shanda Asset Management Holdings reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Shanda Asset Management Holdings sold 10,000 Supernus Pharmaceuticals shares in Q3 2019, an estimated $331K.
Shanda Asset Management Holdings first reported a position in Supernus Pharmaceuticals in Q3 2016 and held it in 12 quarters.
Shanda Asset Management Holdings's Supernus Pharmaceuticals position peaked at $599K in Q2 2018.
243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Shanda Asset Management Holdings's 13F filing for Q3 2019, filed 14 Nov 2019.